Drug development
Developing medicines is a long and risky journey. Many promising compounds fail along the way due to lack of efficacy, safety issues, complex regulatory requirements, or simply insufficient funding.
At RISE, all expertise is gathered under one roof, making it possible to advance projects across different types of APIs, whether it is biologics or small-molecule drugs. Within biologics, including vaccines, antibodies, mRNA, and cell and gene therapies, we focus on formulation, stability, and immunological properties to ensure the API performs as intended. For small-molecule drugs, we ensure robust synthetic routes, high purity, and reproducibility, including safe handling of highly potent APIs (HPAPIs) when required.
Sustainability and regulatory compliance are integrated throughout the process, and we also support companies in navigating opportunities for public funding.
Solution
End-to-end CDMO services for small molecules
Developing small-molecule drug substances requires robust synthesis, scalable processes and regulatorily ready approaches. Early challenges such as solubility, stability and bioavailability must be addressed while navigating a complex regulatory landscape and increasing expectations for sustainable pharmaceutical manufacturing.
Solution
End-to-end CDMO services for biologics
Developing biological drugs – from oligonucleotides, peptides, PROTACs, and conjugates to antibodies and mRNA – places high demands on both substance and product levels. Stability, reproducibility, maintained biological activity, and controlled delivery are critical factors. Advanced formulations, including nanoformulations, require deep expertise in particle characterization, functional analyses, and in vivo behavior.
Expertise in Drug development
Expertise
Vaccine
Vaccine development is a prioritised area to increase global health. At RISE, we offer infrastructure and broad expertise in the field of vaccines. We can guide you through the entire process, from research and regulatory requirements to the finished vaccine.
Expertise
Drug formulation
Formulation development is an important part of the product development of new medicines. A well-designed formulation can have a crucial role for the drug candidate's success clinically. Our formulation scientists have good knowledge of the drug development process and can help from early preformul…
Technology infrastructure
3D-Bioprinting and additive manufacturing
RISE can offer method development, functionalisation and printing via our high-quality EnvisionTEC system: 3D Bioplotter (4th Gen). Manufacturer series) and Perfactory P4 Mini XL.
Learn more about our expertise and equipment
Article
New medicines need capital - and the right development partner
Drug development is at the heart of society. But developing a commercial product is a long, expensive and complex process – and smaller companies can easily get stuck along the way.
"With a long-term development partner, you are more likely to secure everything from funding to expertise and equip…
Article
Green transition for the life sciences sector challenging but possible
The life sciences industry aims to improve human health. At the same time, the sector is responsible for a significant climate impact. And the transition faces particular challenges.
"We in the research community can help to better understand what can be changed and provide relevant assessment met…
Story
Nytänkarpodden möter: Dag Larsson, Lif – de forskande läkemedelsföretagen
Infrastruktur och samverkan står i fokus när Ian Cotgreave, avdelningschef inom kemisk och farmaceutisk toxikologi på RISE möter Dag Larsson, senior sakkunnig policy på Lif – de forskande läkemedelsföretagen, för att diskutera framtidens läkemedelsutveckling i Sverige.
Article
New substance offers hope for a cure against multi-resistant bacteria
The Swiss biotech company Juvabis is developing a new substance, EBL-1003, as part of the ENABLE project. The substance could be used to treat patients with illnesses caused by multi-resistant bacteria.
NextBioForm: Centre for the formulation and processing of biological medicines
NextBioform is a collaboration centre comprising 18 partners from institutes, academia, hospitals and industry. Together, we promote the development and sharing of knowledge with the aim of creating improved biological medicines.
Learn more about NextBioForm
Projects in Drug development
Project
PHARMECO SSbD in Pharma Manufacturing
PHARMECO aims to drive a green transition in the manufacture of medicine and reduce the environmental impact of (bio)pharmaceutical manufacturing routes.
Project
FORMAMP
Kraftiga användning av antibiotika under de senaste årtiondena har lett till att bakterier har utvecklat resistens vilket har orsakat spridning av livshotande sjukdomar. Inom FORMAMP har nanoteknologi i kombination med antimikrobiella peptider ytnytttjats för att utveckla innovativa läkemedelsformu…
Why RISE
01
The entire development chain
– We offer support throughout the entire process, from molecular design and formulation to GMP production for clinical trials. 02
Biological medicines and advanced therapies
– expertise in vaccines, antibodies, mRNA and ATMP, with a particular focus on stability and immune responses. 03
GMP and GLP laboratories
– We regulate the production of materials for use in clinical trials, preclinical safety studies and toxicological analyses. 04
NextBioForm Collaboration Centre
– Platform with 18 partners for method development and verification of biological drug formulations. 05
Green transition and financing
– Supporting sustainable process development in accordance with the principles of green chemistry and navigating public research funds.Relevant areas for you
Production and manufacturing
Swedish industry is facing a major transition, with ever-increasing demands for sustainability, efficiency, and competitiveness. At the same time, di…
Digitalisation
Digitalisation is putting new demands on both businesses and the public sector. Just having access to data isn't enough anymore – the challenge is to…
Chemical products and processes
Chemicals are essential for a functioning society, but the choice of substances and processes determines their impact on the environment and health. …
Innovation management
Competitiveness requires systematic renewal, but many organisations understand the need without being able to put it into practice. Rapid changes, co…
Medtech
Developing a medical technology innovation is a challenging and complex process that requires knowledge, experience and resources. It is not enough t…